At a Glance
- Company: Fujifilm Corporation; VALANX Biotech
- Location: Tokyo, Japan; US-based
- Deal value: Undisclosed strategic investment
- Focus area: Antibody-drug conjugate manufacturing
- Next steps: Capacity expansion, joint ADC development
What happened?
Fujifilm Corporation announced an investment in VALANX Biotech to strengthen its antibody-drug conjugate (ADC) contract development and manufacturing organization (CDMO) services. The partnership builds Fujifilm’s capabilities in ADC production.
Why does it matter?
ADCs represent a fast-growing oncology modality with over $10B in global sales; manufacturing complexity demands specialised CDMOs. Fujifilm gains expertise in conjugation, linker stability and payload handling to capture market share from Lonza and Samsung Biologics.
Who’s behind it?
Fujifilm’s biopharma arm provides viral vector and biologics CDMO services; VALANX specialises in ADC process development. CEOs highlighted complementary technologies for end-to-end ADC solutions.
How was it achieved?
VALANX’s platform optimises drug-antibody ratios and purification; investment enables Fujifilm facilities to handle clinical/commercial ADC scale-up. Joint team accelerates customer timelines.
What’s next?
Expanded ADC capacity online 2027; target phase 3/commercial programmes. Fujifilm eyes ADC partnerships with Big Pharma oncology pipelines.
What are people saying?
Fujifilm exec: “Strategic step… leading ADC CDMO.” VALANX CEO: “Fujifilm’s infrastructure accelerates our vision.”